G. Hortobagyi
Oncology · 2000–2022
A researcher in the Science corpus: 42 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 222 citations into it
Whom G. Hortobagyi trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts G. Hortobagyi overall
Papers from G. Hortobagyi's perspective
Ordered by how strongly the researchers G. Hortobagyi trusts endorse each paper. Same corpus, a different order for every researcher.
- Repeated observation of breast tumor subtypes in independent gene expression data sets (Proceedings of the National Academy of Sciences of the United States of America)
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets (Nature Medicine)
- A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) (Cancer Research)
- Breast cancer classification and prognosis based on gene expression profiles from a population-based study (Proceedings of the National Academy of Sciences of the United States of America)
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications (Proceedings of the National Academy of Sciences of the United States of America)
- SEER Cancer Statistics Review, 1975-2003
- Supervised risk predictor of breast cancer based on intrinsic subtypes.
- Trastuzumab--mechanism of action and use in clinical practice. (New England Journal of Medicine)
- Anticancer drugs: To the rescue? (Nature reviews. Drug discovery)
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. (Cancer Cell)
Their papers
- Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. (2006) — 715 citations
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. (2004) — 1,895 citations
- Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. (2009) — 880 citations
- ESR1 ligand binding domain mutations in hormone-resistant breast cancer (2013) — 1,143 citations
- ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation (2008) — 715 citations
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer (2011) — 2,734 citations
- PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression (2017) — 857 citations
- High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. (2012) — 139 citations
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) — 597 citations
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (2021) — 692 citations
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (2019) — 1,055 citations
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (2018) — 730 citations
- Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer (2018) — 614 citations
- Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. (2017) — 596 citations
- Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual (2017) — 920 citations
- Deubiquitination and Stabilization of PD-L1 by CSN5 (2016) — 727 citations
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity (2016) — 993 citations
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. (2016) — 1,638 citations
- Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. (2014) — 604 citations
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes (2013) — 668 citations